Clinical Trial Update: Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial assessing ruxolitinib in combination with trastuzumab for metastatic HER2-positive breast cancer has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Breast Carcinoma
• Her-2 Positive Breast Cancer

Drugs mentioned

• Ruxolitinib (ruxolitinib)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Dawn L. Hershman | Conditions: Metastatic Breast Cancer, Breast Carcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-08-24